NICE Guidelines on Methylphenidate
Who or what is NICE? 
NICE – The National Institute for Clinical Excellence – was set up as a Special Health Authority for England and Wales on 1 April 1999.
It is part of the British National Health Service (NHS), and its role is to provide patients, health professionals and the public with authoritative, robust and reliable guidance on current ‘best practice?’.
The guidance will cover both individual health technologies (including medicines, medical devices, diagnostic techniques, and procedures) and the clinical management of specific conditions.
NICE offers the NHS and its patients a new service, which we intend shall earn, and retain, the confidence and respect of the community as a whole.
Professor Sir Michael Rawlins
Chair, National Institute for Clinical Excellence
(please note that the Copyright on all material on this page and the links below is held by NICE)
NICE issues Guidance on Methylphenidate (Ritalin/ Equasym) for ADHD – 31 October 2000
The National Institute for Clinical Excellence has today issued its guidance to the NHS in England and Wales on the use of methylphenidate for attention deficit/hyperactivity disorder (ADHD). Use the links below to view the guidance document, the press release and the HTA report.
Press release
Full Guidance (pdf) (You will need Adobe Acrobat to download this file; it is available at www.adobe.com (for Windows) or http://www.adobe.com/support/downloads/acrmac.htm (for Mac)
Full Guidance (text)
HTA report
Questions and Answers
Contacting NICE
A summary of the NICE Guidelines was produced recently by Jenny Lyon (IPS) and is now available CLICK HERE
